COMMUNIQUÉS West-GlobeNewswire

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
17/01/2024
Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increases mortality rates [...]
DiagnaMed Announces Pilot Launch of CERVAI™ Brain Health AI Solution
17/01/2024
TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced [...]
Venus Concept Launches Venus Prime
17/01/2024
TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the launch of Venus Prime, a structured in- [...]
Manitoba Harvest Hemp Foods Celebrates a Decade of B Corp Certification With a Score of 100 Points
17/01/2024
Leading Global Hemp Foods Brand Reinforces their Commitment to the Global B Corp Community NEW YORK and WINNIPEG, Manitoba, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Manitoba Harvest , a pioneer and leader in hemp-based foods [...]
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
17/01/2024
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
17/01/2024
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of [...]
Gritstone bio to Participate in Upcoming Investor Conference
17/01/2024
EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will [...]
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
17/01/2024
Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by GV and F-Prime Capital Significant investment by top-tier syndicate endorses [...]
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
17/01/2024
LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report
17/01/2024
Report highlights latest biosimilar pricing and market share status, including state of the adalimumab market Biosimilar Deep Dive section illustrates patient benefit from lower adalimumab cost options using the [...]
Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings
17/01/2024
Postponement of the decision on the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings Paris, France, January 17, 202 4 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth [...]
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire
17/01/2024
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire Paris, France, 17 janvier 2024 – 07h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 [...]
Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd
16/01/2024
The Combined Company Is Expected To Trade On Nasdaq Post-Closing Under A New Ticker Symbol Mediforum is a leading biotechnology company in Korea that focuses on researching and developing ethical drugs and diagnostic [...]
Arvinas Appoints Jared Freedberg as General Counsel
16/01/2024
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company [...]
New ReNu® Data from Organogenesis Highlighted at ICRS 2019 World Congress
05/10/2019
CANTON, Mass. and VANCOUVER, British Columbia, Oct. 05, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and [...]
Pure Sunfarms, la coentreprise d'Emerald Health Therapeutics, commence à expédier ses produits de marque à base de cannabis à un grossiste de la province de la Colombie-Britannique
05/10/2019
VANCOUVER, Colombie-Britannique, 04 oct. 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV : EMH ; OTCQX : EMHTF), a annoncé aujourd'hui que sa coentreprise détenue à 50 % pour la production [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/10/2019
CRESTWOOD, Ky. and WALTHAM Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer
04/10/2019
CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/10/2019
BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425 [...]

Pages